Denmark-based medical foundation Novo, which invests $300m per year through its corporate venturing funds, has reinvested in US-based drugs company Logical Therapeutics’ in its third round of funding. Logical raised $16.9m in its series C round led by venture capital firms SV Life Sciences (SVLS) and Novitas Capital and including merchant bank and VC Burrill…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
